Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.51 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PRLHR | P49683 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19301133 | 0.87 | ITGA5 (0.51) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19283598 | 0.84 | ITGA5 (0.48) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19283529 | 0.83 | ITGA5 (0.48) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19283527 | 0.82 | ITGA5 (0.47) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19283550 | 0.82 | ITGA5 (0.47) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19301231 | 0.82 | ITGA5 (0.46) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19283587 | 0.81 | ITGA5 (0.46) | ITGA5ITGB6ITGB8CACNA2D1CACNA1B | |
| SCHEMBL19283613 | 0.80 | ITGB6 (0.55) | ITGA5ITGB6ITGB8SMN1; SMN2NPC1 | |
| SCHEMBL20743761 | 0.79 | NPC1 (0.47) | ITGA5ITGB6ITGB8RAF1BRAF | |
| SCHEMBL19283637 | 0.79 | ITGA5 (0.47) | ITGA5ITGB6ITGB8RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | claimed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | claimed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | claimed |
| EP-3419973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2019-01-02 | — | — | EP | claimed |
| WO-2017144183-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2017-08-31 | — | — | WO | claimed |
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | disclosed |
| EP-3419973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144183-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNN2, KCNN1 | ITGA5 3161/4885ITGB6 3120/4885ITGB8 3935/4885 |
| US-11274092-B2 | Potassium channel inhibitors | KCNJ2, KCNJ11, KCNJ1 | ITGA5 2293/4885ITGB6 2913/4885ITGB8 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.